Financial Performance - Revenue for Q2 2021 was $160.5 million, a 91% increase year-over-year compared to $84.0 million in Q2 2020[7] - Adjusted EBITDA for Q2 2021 was $14.5 million, a 39% increase year-over-year compared to $10.5 million in Q2 2020[7] - The company has a strong balance sheet with a cash position of $276 million[7] - TTM (Trailing Twelve Months) Revenue is $524 million[8] Growth and Expansion - Total clinicians reached 3,975, up 94% year-over-year, with 674 net clinician additions in Q2 2021[7] - The company operates in 31 states with 450+ centers[10, 16, 18] - 35 de novo centers were opened in Q2 2021, part of 183 opened since inception[16] - 10 acquisitions were completed in Q2 2021, part of 64 acquisitions completed since inception[16] Market and Strategy - The company is well-positioned for continued market share gains in the $116 billion mental health market[10] - The company estimates the total addressable market (TAM) will grow to $215 billion by 2025, representing a 14% CAGR (Compound Annual Growth Rate)[17] Social Responsibility - The LifeStance Health Foundation was established with an initial endowment of $10 million[7, 13]

LifeStance Health Group, Inc. (NASDAQ:LFST) Q2 2021 Earnings Conference Call August 11, 2021 5:00 PM ET Company Participants Michael Lester - Chief Executive Officer Danish Qureshi - Chief Growth Officer Mike Bruff - Chief Financial Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Ryan Daniels - William Blair Lisa Gill - JPMorgan Steph Wissink - Jefferies Jamie Perse - Goldman Sachs Operator Good afternoon everyone and welcome to LifeStance Health Second Quarter 2021 Conference Call. ...

Company Overview - As of June 30, 2021, LifeStance Health Group employed nearly 4,000 licensed mental health clinicians, making it one of the largest outpatient mental health platforms in the U.S.[161] - The company completed its IPO on June 14, 2021, issuing 32,800,000 shares at $18.00 per share, resulting in net proceeds of $548.9 million after expenses[167]. - The company estimates a significant opportunity to grow its employed clinician base from nearly 4,000 to a potential 650,000 mental health clinicians in the U.S.[178]. Patient Outcomes - A survey of over 20,000 patients indicated that 53% reported improvement in depression symptoms and 54% in anxiety symptoms after two visits, with 81% reporting decreased suicidal ideation[163]. - The COVID-19 pandemic has increased patient demand for mental health services, with 41% of adults reporting adverse mental health conditions related to the pandemic[171]. - LifeStance Health Group believes the pandemic will lead to a paradigm shift in mental health care focus, positively impacting the industry for years to come[174]. Financial Performance - Total revenue for the three months ended June 30, 2021, was $160.5 million, compared to $45.5 million for the same period in 2020, representing a growth of 253%[205]. - For the six months ended June 30, 2021, total revenue was $303.7 million, up from $111.7 million in the same period in 2020, indicating a growth of 171%[206]. - Adjusted EBITDA for the three months ended June 30, 2021, was $14.5 million, compared to $6.0 million for the same period in 2020[204]. Operational Strategy - The company has built a powerful organic growth engine, expanding center capacity and patient visits within existing centers[175]. - The de novo center strategy has resulted in the opening of 183 centers since inception, with 63 centers opened in 2021 alone[185]. - De novo centers typically break even within 2 to 4 months and achieve a two-times return on invested capital within 18 months[186]. Cost Management - LifeStance Health Group's model demonstrates that $1 spent on collaborative mental health care saves $6.50 in total medical costs, highlighting significant cost-saving opportunities for payors[163]. - Center costs, excluding depreciation and amortization, for the three months ended June 30, 2021, were $109.3 million, primarily driven by $95.9 million in center-based compensation[207]. - General and administrative expenses for the three months ended June 30, 2021, totaled $85.5 million, with $29.5 million attributed to stock-based compensation[211]. Debt and Cash Management - Cash and cash equivalents as of June 30, 2021, totaled $276.2 million, expected to be sufficient to fund operating and capital needs for at least the next 12 months[226]. - The company had an aggregate principal amount of $161.9 million outstanding under the May 2020 Credit Agreement as of June 30, 2021[228]. - The company expects cash generation from operations to be sufficient to repay outstanding debt obligations and lease payments[228]. Future Outlook - The company aims to expand its market footprint by entering new markets and acquiring high-quality practices with established payor relationships[187]. - The company plans to further integrate mental health services with primary care providers to enhance patient access and care coordination[181]. - The company is classified as an emerging growth company and has elected to use an extended transition period for complying with new accounting standards[242].